BioPharma

CSPC Pharmaceutical and AstraZeneca form Biologics Joint Venture

Yuvraj — Thu, 06 Aug 2026 12:04:34 +0000

CSPC Pharmaceutical and AstraZeneca have signed a joint venture contract to establish a new-generation production facility in Shijiazhuang, China. The collaboration focuses on the manufacturing and global supply of mutually agreed biologics drug substances, with capital contributions structured at a 51:49 equity ratio in favor of CSPC Pharmaceutical. The agreement remains subject to customary closing […]

The post CSPC Pharmaceutical and AstraZeneca form Biologics Joint Venture first appeared on World Pharma Today.

Industrial Water Reuse Supporting Biopharma Manufacturing

Yuvraj — Mon, 27 Jul 2026 10:52:39 +0000

The biopharmaceutical industry is one of the most water-intensive sectors of the global economy, requiring quantities of high-purity water for media preparation, equipment cleaning, and final product formulation. As global water scarcity increases and regulatory pressure on environmental sustainability intensifies, manufacturers are increasingly turning to circular water strategies. Industrial water reuse supporting biopharma manufacturing involves […]

The post Industrial Water Reuse Supporting Biopharma Manufacturing first appeared on World Pharma Today.

Formulation Analytics Accelerating Biologic Development

Yuvraj — Tue, 21 Jul 2026 13:11:26 +0000

The development of biological drugs is an intricate process that requires a meticulous understanding of the physical and chemical properties of large, complex proteins. Unlike small molecules, biologics are highly sensitive to their environment, and even minor changes in temperature, pH, or mechanical stress can lead to denaturation or aggregation. To manage these risks, the […]

The post Formulation Analytics Accelerating Biologic Development first appeared on World Pharma Today.

Combination Product Design Advancing Biologic Delivery

Yuvraj — Tue, 21 Jul 2026 12:47:03 +0000

The pharmaceutical sector has witnessed a significant shift toward the development of biologics, which now constitute a substantial portion of the global drug pipeline. Unlike small molecules, biologics are typically large, complex proteins that require parenteral administration due to their susceptibility to degradation in the gastrointestinal tract and their inability to cross biological membranes easily. […]

The post Combination Product Design Advancing Biologic Delivery first appeared on World Pharma Today.

CDMO Strategies Powering the Next-Gen Biopharma Surge

Yuvraj — Sat, 27 Jun 2026 07:51:15 +0000

The biopharmaceutical sector is currently navigating an era of unprecedented growth and technological complexity. As the global drug pipeline shifts toward advanced modalities such as cell and gene therapies, bispecific antibodies, and complex mRNA formulations, the demands placed on manufacturing infrastructure have reached a critical point. Many emerging biotech firms and even established pharmaceutical giants […]

The post CDMO Strategies Powering the Next-Gen Biopharma Surge first appeared on World Pharma Today.

Extracellular Vesicles and the Future of Cell-Free Therapy

Yuvraj — Sat, 27 Jun 2026 07:49:49 +0000

The transition from living cell therapies to cell free alternatives represents one of the most significant shifts in modern biotechnology. For years, the regenerative medicine sector has relied on the transplantation of whole cells to repair tissues and modulate the immune system. While these approaches have shown clinical efficacy, they are often hindered by complex […]

The post Extracellular Vesicles and the Future of Cell-Free Therapy first appeared on World Pharma Today.

Cell and Gene Therapy Delivery Challenges Evolving Now

Yuvraj — Fri, 26 Jun 2026 06:23:54 +0000

We are currently standing at the threshold of a medical revolution, transitioning from a model of managing chronic conditions to one of potentially curing genetic diseases at their foundational level. The promise of advanced therapeutics such as CRISPR-based gene editing and CAR-T cell therapies is immense, offering hope for conditions that were once considered incurable. […]

The post Cell and Gene Therapy Delivery Challenges Evolving Now first appeared on World Pharma Today.

The Engine of Cell Therapy Success: Why Analytical Development Determines Whether Promising Cell Therapies Reach Patients

Yuvraj — Fri, 12 Jun 2026 09:57:32 +0000

How advanced analytical methods, potency assays, and immune profiling are shaping the future of cancer cell therapies Cell therapies have transformed the treatment landscape for patients with cancer and other serious diseases. Innovations such as CAR-T cell therapies have demonstrated remarkable clinical success, offering new treatment options for patients with limited alternatives. While much of […]

The post The Engine of Cell Therapy Success: Why Analytical Development Determines Whether Promising Cell Therapies Reach Patients first appeared on World Pharma Today.

Daewoong and Chime Biologics Partner for Biosimilar Push

Yuvraj — Wed, 10 Jun 2026 12:09:36 +0000

Chime Biologics and Daewoong Pharmaceutical have entered into a strategic collaboration to develop and manufacture a dupilumab biosimilar candidate referencing Dupixent for global markets. The partnership, announced by VMS Group, combines the development and manufacturing capabilities of Chime Biologics with Daewoong Pharmaceutical’s plans to expand its presence in the international biosimilars sector. Through this initiative, […]

The post Daewoong and Chime Biologics Partner for Biosimilar Push first appeared on World Pharma Today.

GNI Group to Acquire Ayumi Pharmaceutical Holdings, Expanding Its Global Biopharmaceutical Position

Yuvraj — Tue, 09 Jun 2026 07:58:55 +0000

GNI Group Co., Ltd. has announced an agreement to acquire 100% of the shares of Ayumi Pharmaceutical Holdings Co., Ltd. from a group of shareholders led by Blackstone, in a transaction that values Ayumi Pharmaceutical Holdings at approximately ¥44.8 billion. The deal will make Ayumi a wholly owned subsidiary of GNI Group and significantly expands […]

The post GNI Group to Acquire Ayumi Pharmaceutical Holdings, Expanding Its Global Biopharmaceutical Position first appeared on World Pharma Today.